Right Technologies, Patient-Centric Collaborations

Apr 22, 2013
Learn how UBC is collaborating with our clients to use technology in advancing patient-centric care.
  • Diabetes

Pharmaceutical companies conducting clinical trials now have access to many new technologies and innovations such as wireless medical devices, interoperability advancements and smartphone applications. The challenge lies in bringing together the right technologies and the right partners to create a study that is both patient-centric and engaging for the participant.

The Patient & Physician Services team at UBC, an Express Scripts subsidiary, is launching a study in collaboration with Boehringer Ingelheim GmbH and Healthrageous (a digital health management provider) for patients with Type 2 diabetes. The study is designed to evaluate a lifestyle modification program that uses online digital tools to help participants better manage their Type 2 diabetes. Patients participate by completing a diabetes lifestyle assessment and an action plan.

The action plan integrates interactive digital coaching about targeted lifestyle factors, blood glucose data from a wireless glucose meter, medication adherence self-tracking, social community, individual challenges and incentives to help patients better manage their disease.

Combined with claims data, this information also can be used to measure healthcare utilization costs and other health outcomes. This innovative study could change the way diabetes patients monitor their health and open up a new level of convenience for patients participating in clinical studies.

To learn more about the study and the collaboration between UBC and Boehringer Ingelheim, join us April 24 at Partnerships in Clinical Trials 2013 for my presentation: Leveraging Data and Innovative Technologies to Achieve Superior Patient Engagement and Biometric Health Improvement in Patients With Diabetes.

You can also listen to a podcast I recorded along with Larry Brooks, director, Business Model & Healthcare Innovation, Boehringer Ingelheim.

comments powered by Disqus